Neurocognitive Dysfunction

10

Review clinical trials related to Neurocognitive Dysfunction. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome

Post-COVID-19 syndrome is an assembly of symptoms, following an infection with Coronavirus disease 2019 (COVID-19). The syndrome is characterized by cognitive impairment, fatigue, sleep disorders, smell and taste disorders, pain and more. This long-term sequela can last for months after recovering from the virus, and no treatment is known to date. The aim of this study is to compare the effect of HBOT vs. Sham on post COVID-19 syndrome

Participants needed: 91
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Assaf-Harofeh Medical CenterUpdated: Apr 21, 2026Locations: 1
Eligibility criteria

Age above 18 years [+2]

Inability to attend scheduled clinic visits and/or comply with the study protoco... [+9]

Status: Not yet recruiting

Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function

Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood. The goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are: How does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients? Which clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes? Participants will: Complete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills. Undergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up). Wear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT. Complete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces. Have medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management. This study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.

Participants needed: 100
Trial details
Age: 0-18Biological sex: AllType: ObservationalSponsor: Rigshospitalet, DenmarkUpdated: Feb 20, 2026Locations: 1
Eligibility criteria

Recipient of allogeneic HSCT in the study period [+3]

Status: Recruiting

Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)

The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called "Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize connections. This study will evaluate RS-tDCS+ for improving complex attention in Active Duty Service Members (ADSM) and Veterans with a history of mTBI. Different tests of complex attention and symptom questionnaires will be used to determine the effects of real versus sham (placebo) RS-tDCS+. Second, the investigators will investigate electrical and connectivity changes in the brain associated with RS-tDCS+ using electroencephalogram (EEG) and magnetic resonance imaging (MRI). Third, the investigators will investigate the lasting effects of any observed changes by evaluating participants at 1 and 6 weeks post-treatment. Lastly, the investigators will explore the impact of individual differences (e.g., PTSD, depression, sleep quality, time since injury, baseline impairment, age, sex, ADSM versus Veteran) on treatment outcome.

Participants needed: 160
Trial details
Age: 18-60Biological sex: AllType: InterventionalSponsor: United States Naval Medical Center, San DiegoUpdated: Nov 12, 2025Locations: 2
Eligibility criteria

Active-Duty Service Members. [+6]

Presence of a medical, psychiatric, physical or non-physical disease, disorder,... [+8]

Status: Recruiting

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.

Participants needed: 40
Trial details
Age: 18-89Biological sex: AllType: ObservationalSponsor: Mclean HospitalUpdated: Nov 6, 2025Locations: 1
Eligibility criteria

Ability of the participant and/or his/her legally authorized representative to u... [+8]

Current serious or unstable medical or neurological condition that could affect... [+17]

Status: Recruiting

Ca-Mg Butyrate in GWI

The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.

Participants needed: 120
Trial details
Phase: Phase 2Age: 40-70Biological sex: AllType: InterventionalSponsor: VA Office of Research and DevelopmentUpdated: Oct 31, 2025Locations: 3
Eligibility criteria

Gulf war era veteran deployed 40 and 70 years old, in good health by medical his... [+1]

Untreated schizophrenia, [+15]

Status: Recruiting

Early Severe Illness TrAnslational BioLogy InformaticS in Humans

Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and/or the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive. The purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUpdated: Oct 6, 2025Locations: 1Duration: 24 Months
Eligibility criteria

Age ≥18 years old [+6]

Age <18 years old [+3]

Status: Not yet recruiting

Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT

Today the overall survival of childhood cancers has increased to above 85%. This increase is partially caused by treatment with bone marrow transplantation. A bone marrow transplantation is an efficient treatment against high-risk leukemia, as well as other life-threatening immunological and hematological diseases. However, it is unfortunately also related to the risk of developing a long series of late effects during early adulthood, such as reduced muscle mass, cardiovascular disease and diabetes. Some survivors of bone marrow transplantation in childhood also seem to experience changes in cognitive functions. These changes may be experienced as difficulties with concentration, forgetfulness, learning difficulties, and challenges in school or the labour market. Currently, the extent of cognitive changes following bone marrow transplantation in childhood is not fully understood, nor how it relates to other late effects, and what can be done to prevent cognitive impairment. This research project will examine cognitive function in a group of survivors of bone marrow transplantation in childhood and find out whether there is a correlation between reduced cognitive function and the occurrence of other late effects, including metabolic changes and reduced physical capacity. It will also explore associations between cognitive function at late follow up and blood-based biomarkers of neurological damage and systemic inflammation at the time of transplantation to identify predictors of reduced cognitive function. The goal of the study is to evaluate the level of cognitive functioning after bone marrow transplantation in childhood, see how it relates to other late effect and identify risk factors and biomarkers in the blood that can predict which patients are at risk of neurocognitive impairment. The results of this study will hopefully contribute to optimizing the prevention and treatment of cognitive impairments following bone marrow transplantation in childhood, thereby improving the quality of life for survivors of bone marrow transplantation in childhood.

Participants needed: 175
Trial details
Age: 7+Biological sex: AllType: ObservationalSponsor: Rigshospitalet, DenmarkUpdated: Sep 4, 2025Locations: 1
Eligibility criteria

=/> 7 years of age [+3]

diagnosed with infantile autism before their HSCT [+1]

Status: Recruiting

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Participants needed: 101
Trial details
Phase: Phase 3Age: 5-39Biological sex: AllType: InterventionalSponsor: Tata Memorial CentreUpdated: Apr 9, 2025Locations: 1
Eligibility criteria

Age at irradiation: 5 to 39 years [+3]

Re-irradiation [+2]

Status: Recruiting

Assessing Neurocognition After Cerebrovascular Intervention

Decreased blood flow to the brain can cause decreased cognitive function. Carotid disease can result in decreased blood flow to the brain. The investigators seek to assess this relationship prospectively through performing a battery of neurocognitive assessments, collection of serum markers of inflammation, and through neuroimaging at two points before intervention (2 months and 1 month before stenting) and at two points after intervention (1 month and 2 months after intervention). The goal is to provide prospective evidence to identify the extent to which carotid stenosis and hypoperfusion of the brain results in diminished neurocognitive performance, and see if serum biomarkers before and after stenting correlate with these findings.

Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, San DiegoUpdated: Feb 6, 2025Locations: 1
Eligibility criteria

patients >18 years of age [+1]

patients <18 years of age [+4]

Status: Recruiting

The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders

The goal of this clinical trial is to test a new digital therapeutic solution which combines a holistic, multidimensional rehabilitation program based on dance and music with an innovative motivational system (DANCEREX-DTx) in Chronic Neurological Disorders (Multiple Sclerosis and pre-Mild Cognitive Impairment - MCI/ MCI at risk of Alzheimer's Disease). The main questions it aims to answer are 1\] efficacy of the digital therapeutic solution in terms of adherence, clinical/functional measures, quality of life and surrogate measures; 2\] usability and acceptability of the system. Participants will be randomized (with an allocation ratio of 2:2:1) into the experimental group (DANCEREX - 24 sessions of multidimensional dance-based program integrated with an innovative motivational system), active comparator group (24 sessions of multidimensional dance-based program) and placebo group (24 sessions of educational program). Researchers will compare the experimental group to the other two groups to see if a digital therapeutic solution integrating a multidimensional dance-based program and motivational system is effective in increasing adherence to rehabilitation treatment.

Participants needed: 192
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Fondazione Don Carlo Gnocchi OnlusUpdated: Jan 10, 2025Locations: 3
Eligibility criteria

age between 18 and 85 years (adult and older adult); [+4]

presence of comorbidities that prevent patients from undertaking a safe home pro... [+4]